Title |
Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
|
---|---|
Published in |
Protein & Cell, April 2017
|
DOI | 10.1007/s13238-017-0411-9 |
Pubmed ID | |
Authors |
Hua Li, Yangbing Zhao |
Abstract |
Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has recently been undergoing rapid development. However, there are still some major challenges, including precise tumor targeting to avoid off-target or "on-target/off-tumor" toxicity, adequate T cell infiltration and migration to solid tumors and T cell proliferation and persistence across the physical and biochemical barriers of solid tumors. In this review, we focus on the primary challenges and strategies to design safe and effective CAR T cells, including using novel cutting-edge technologies for CAR and vector designs to increase both the safety and efficacy, further T cell modification to overcome the tumor-associated immune suppression, and using gene editing technologies to generate universal CAR T cells. All these efforts promote the development and evolution of CAR T cell therapy and move toward our ultimate goal-curing cancer with high safety, high efficacy, and low cost. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | <1% |
Unknown | 204 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 43 | 21% |
Researcher | 26 | 13% |
Student > Ph. D. Student | 24 | 12% |
Student > Master | 24 | 12% |
Other | 9 | 4% |
Other | 24 | 12% |
Unknown | 55 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 39 | 19% |
Immunology and Microbiology | 27 | 13% |
Agricultural and Biological Sciences | 26 | 13% |
Medicine and Dentistry | 25 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 4% |
Other | 20 | 10% |
Unknown | 60 | 29% |